Introduction
Governance and oversight of GMEC is provided by the Board of the company. Sir Keith Peters was appointed Chairman of GMEC in 2008 and Dr Jim Hagan took up the position of CEO in June 2009. The GMEC Board consists of experienced members drawn from industry, healthcare and academia.
Scientific strategy and oversight is the responsibility of the Cluster Committee, composed of senior staff from the industrial partners, the heads of the University Medical Schools and CEOs from the NHS Trusts.
Since its inception, GMEC has built a portfolio of research initiatives focused on therapeutic areas, bioscience and capability development. Research activities range from basic biology (physiology, inflammation) to specific disease related research (asthma) and innovative technology (imaging, nanotechnology). Each programme brings together leading researchers from across the partner universities with agreed research objectives and plans.
For further information on the programme scientists and research, please see GMEC Programmes.
